Endometriosis Global Market Report 2024 - By Demand, Share, Size, Report, Outlook By 2033

The endometriosis market size has grown rapidly in recent years. It will grow from $1.27 billion in 2023 to $1.4 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to delayed diagnosis and increased awareness, advances in laparoscopic surgery, hormonal therapies, patient advocacy and support groups.

The endometriosis market size is expected to see strong growth in the next few years. It will grow to $2.01 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to minimally invasive procedures, pharmaceutical innovations, genetic and epigenetic research, global expansion of women's healthcare. Major trends in the forecast period include patient-centered care, precision medicine, virtual care and telemedicine, fertility preservation.

Market Overview -
Endometriosis is a chronic medical condition that occurs when tissue similar to the lining of the uterus (endometrium) grows outside the uterus. The condition can cause severe pain in the pelvis and make it harder to get pregnant. It can significantly impact a person's quality of life and fertility.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13035&type=smp

Elevated Ovarian Cancer Incidence Fuels Growth In The Endometriosis Market
The increasing incidence of ovarian cancer is expected to propel the growth of the endometriosis market going forward. Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs and the hormones estrogen and progesterone. Endometriosis is associated with an increased risk of developing epithelial ovarian cancer, mainly the endometrioid and precise cell cancer subtypes, characterized by high estrogen concentrations, which can increase the risk of developing ovarian cancer. For instance, in January 2023, according to the American Cancer Society, a US-based professional organization, it is projected that approximately 19,710 new cases of ovarian cancer will be diagnosed among women in the US in 2023. Furthermore, in 2022, according to the Ovarian Cancer Research Alliance, a US-based not-for-profit organization, ovarian cancer caused 12,810 deaths in 2022 and increased to 13,270 fatalities in 2023. Therefore, the increasing incidence of ovarian cancer is driving the growth of the endometriosis market.

Competitive Landscape -
Major players in the endometriosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck And Co. Inc., Abbvie Inc., Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, AstraZeneca PLC, Abbott Laboratories, Eli Lilly and Company, Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Ipsen Pharma Biotech S.A.S., Cadila Pharmaceuticals Ltd., Gedeon Richter PLC, Torrent Pharmaceuticals Ltd., Neurocrine Biosciences Inc., Ferring Pharmaceuticals, Prestige Consumer Healthcare Inc., Almirall S.A, Evotec BioSystems GmbH, Serum Institute of India Pvt. Ltd., Kissei Pharmaceutical Co. Ltd., Sanofi India Ltd., DebioPharm Group, Repros Therapeutics Inc., Meditrina Pharmaceuticals Private Limited, Zenomed Healthcare Private Limited.

Innovative Medications Reshaping Endometriosis Treatment Landscape
Major companies operating in the endometriosis market are focused on developing innovative drugs such as Myfembree and getting approvals to provide new patient treatment options. The introduction of novel endometriosis medications addresses a previously unmet demand for effective treatments. For instance, in August 2022, Myovant Sciences GmbH, a Switzerland-based biopharmaceutical company and Pfizer Inc., a US-based pharmaceutical industry company, received approval for Myfembree from the U.S. Food and Drug Administration (FDA) for the management of moderate to severe pain associated with endometriosis in premenopausal women. Myfembree is a once-daily pill that combines three essential ingredients such as relugolix, estradiol and norethindrone acetate. It provides proven relief for premenopausal women with two indications in one pill. This provides an alternative treatment option for women who cannot or prefer not to use hormone therapy.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/endometriosis-global-market-report

Key Segments -
The endometriosis market covered in this report is segmented -
1) By Type: Superficial Peritoneal Lesion; Endometrioma; Deeply Infiltrating Endometriosis; Other Types
2) By Treatment Type: Hormonal Therapy; Pain Management
3) By Drug: Oral Contraceptives; Progestins; Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Gonadotropin Releasing Hormone (GnRH) Analogues; Levonorgestrel-Releasing Intrauterine Devices (LNR-IUDs); Other Drugs
4) By End-User: Hospitals; Homecare; Specialty Centers; Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model"

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.